ated adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources).

Antimalarial Medications
Although efficacy and subsequent optimal dosing in COVID-19 is still under investigation, both chloroquine and hydroxychloroquine are currently FDA-approved in the United States for other indications (ie, malaria and systemic lupus erythemat